Current management and future strategies of gastric cancer

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 248-257

  Lee, Joong Ho ^a   Kim, Kyung Min ^a   Cheong, Jae Ho ^a   Noh, Sung Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biological marker; Gastrectomy; Lymphadenectomy; Molecular therapeutics; Primary prevention; Screening; Stomach neoplasm

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PLACEBO; TRASTUZUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER SURGERY; CHEMORADIOTHERAPY; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; ENDOSCOPIC MUCOSAL RESECTION; GASTRECTOMY; HUMAN; LYMPHADENECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PRIMARY PREVENTION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; STOMACH CANCER; SURVIVAL RATE;

DISEASE MANAGEMENT; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; STOMACH NEOPLASMS;

EID: 84863182031     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.248     Document Type: Article

References (68)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640-6.
4. The World Health Organization's fght against cancer: strategies that prevent, cure and care. Available from URL: http://www.who.int/entity/cancer/WHA_cancer_presentation_fnal.pdf. [Accessed Sep 5 2011]
5. Demark-Wahnefried W, Rock CL, Patrick K, Byers T. Lifestyle interventions to reduce cancer risk and improve outcomes. Am Fam Physician 2008;77:1573-8.
6. Plummer M, Franceschi S, Muñoz N. Epidemiology of gastric cancer. IARC Sci Publ 2004:311-26.
7. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Overweight, obesity and gastric cancer risk: results from a meta-analy-sis of cohort studies. Eur J Cancer 2009;45:2867-73.
8. Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2011. [Epub ahead of print]
9. Lunet N, Lacerda-Vieira A, Barros H. Fruit and vegetables consumption and gastric cancer: a systematic review and meta-analy-sis of cohort studies. Nutr Cancer 2005;53:1-10.
10. Schistosomes, liver fukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
11. Eslick GD. Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. World J Gastroenterol 2006;12:2991-9.
12. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
13. Correa P. Human gastric carcinogenesis: a multistep and multifacto-rial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
14. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-71.
15. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151:121-8.
16. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
17. Helicobacter pylori in peptic ulcer disease. NIH Consens Statement 1994;12:1-23.
18. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early He-licobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-8.e1-2.
19. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011;8:133-40.
20. Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009;200:1311-7.
21. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalig-nant gastric lesions. Gut 2002;50:378-81.
22. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011;43:1-11.
23. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008;9:279-87.
24. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006;4:709-16.
25. Lee KS, Oh DK, Han MA, Lee HY, Jun JK, Choi KS, et al. Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat 2011;43:83-8.
26. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38:259-67.
27. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006;12:4873-4.
28. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7.
29. Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T, Linnala A, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atro-phic gastritis: an observational case-control study. Scand J Gastro-enterol 2002;37:785-91.
30. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
31. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jes-sup J, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009;27.
32. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joy-paul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-30.
33. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
34. Sano T, Yamamoto S, Sasako M; Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002;32:363-4.
35. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
36. Degiuli M, Sasako M, Ponti A; Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010;97:643-9.
37. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsu-ka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-73.
38. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Ku-rita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
39. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-23.
40. An JY, Pak KH, Inaba K, Cheong JH, Hyung WJ, Noh SH. Relevance of lymph node metastasis along the superior mesenteric vein in gastric cancer. Br J Surg 2011;98:667-72.
41. Masuda TA, Sakaguchi Y, Toh Y, Aoki Y, Harimoto N, Taomoto J, et al. Clinical characteristics of gastric cancer with metastasis to the lymph node along the superior mesenteric vein (14v). Dig Surg 2008;25:351-8.
42. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25.
43. Imamura H, Kurokawa Y, Kawada J, Tsujinaka T, Takiguchi S, Fujiwara Y, et al. Infuence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer: results of a randomized controlled trial. World J Surg 2011;35:625-30.
44. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer 2007;10:1-11.
45. Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assist-ed Billroth I gastrectomy. Surg Laparosc Endosc 1994;4:146-8.
46. Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S. Long-term quality of life after laparoscopy-assisted distal gastrec-tomy for gastric cancer. Surg Endosc 2007;21:2150-3.
47. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III mul-ticenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-20.
48. Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, et al. Safety and feasibility of laparoscopy-assisted distal gastrecto-my with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer 2010;13:238-44.
49. Oh SJ, Hyung WJ, Song J, Kang W, Choi SH, Noh SH. A simple method for trimming of the lesser and greater curvature using "Bovie" in gastric cancer surgery. Hepatogastroenterology 2009; 56:1765-7.
50. Hyung WJ, Lee JH, Lah KH, Noh SH. Intraoperative needle decompression: a simple alternative to nasogastric decompression. J Surg Oncol 2001;77:277-9.
51. Kim MC, Park SY, Jung GJ, Kim HH, Noh SH. The usefulness of intraoperative needle decompression of the colon during radical gastrectomy--a prospective and randomized trial. Hepatogastroen-terology 2004;51:97-99.
52. Kim J, Lee J, Hyung WJ, Cheong JH, Chen J, Choi SH, et al. Gastric cancer surgery without drains: a prospective randomized trial. J Gastrointest Surg 2004;8:727-32.
53. Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006;12:3237-42.
54. Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. Semin Radiat Oncol 2002;12:150-61.
55. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykows-ki T, Michiels S, Ohashi Y, Pignon JP, et al. Beneft of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-37.
56. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fuoropyrimidine. N Engl J Med 2007;357:1810-20.
57. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. J Clin Oncol 2011;29:4387-93.
58. Bang Y, Kim YW, Yang H, Chung HC, Park Y, Lee K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the phase III CLASSIC trial. 2011 ASCO Annual Meeting: J Clin Oncol 2011:29.
59. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003;21:274s-275s.
60. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
61. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-21.
62. Ryu KW, Eom BW, Nam BH, Lee JH, Kook MC, Choi IJ, et al. Is the sentinel node biopsy clinically applicable for limited lymphad-enectomy and modifed gastric resection in gastric cancer? A me-ta-analysis of feasibility studies. J Surg Oncol 2011;104:578-84.
63. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010;36:235-48.
64. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
65. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-97.
66. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as frst-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76.
67. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Ca-panu M, et al. Phase II study of modifed docetaxel, cisplatin, and fuorouracil with bevacizumab in patients with metastatic gastro-esophageal adenocarcinoma. J Clin Oncol 2011;29:868-74.
68. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63.